

Index

- access to medicines
 - in developing countries, 1–4, 28
 - government role in, 2
 - health spending on, 1
 - household costs and, 1
 - model of human rights and, 165–6
 - patent policy space and, 4–10
 - patent rights and, 41–2
 - poverty and, 1
 - under TRIPS Agreement, 2
- African Regional Intellectual Property Organization (ARIPO), 106–7
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement)
 - access to medicines under, 2
 - Article 6, 7, 17
 - Article 7, 95
 - Article 8, 17
 - Article 8.1, 15, 17, 21, 95
 - Article 27, 17
 - Article 27–34, 14
 - Article 27(1), 2–3, 14, 95
 - Article 27(2), 14–15, 56
 - Article 27(3), 14–15
 - Article 28, 15
 - Article 30, 17–19
 - Article 31, 7, 17, 23
 - Article 31(b), 17, 22–3
 - Article 31(f), 22–3
 - Article 31(k), 17
 - Article 33, 15
 - Article 65(2), 2–3
 - Article 65(4), 2–3
 - Article 66(1), 2–3
 - Doha Declaration, 19–24, 95–6
 - model of human rights and, 24
 - Paragraph 4, 66
 - TRIPS Agreement and Public Health, 101
- Draft Ministerial Declaration, 17–29
- flexibilities of, 93, 95–6
- India and, 137–8
- least-developed countries and, 16
- loopholes in, 93
- model of human rights compatibility with, 69
- patent policy space and, 4–7, 14–24
 - development of, before TRIPS Agreement, 10–14
- patent rights under, 2–3
- Patents Act and, 118–19
- pharmaceutical patents under, 2–3
- right to health and, 94–102
 - model of human rights, 94–102
 - World Trade Organization dispute settlement panels and, 100–2
- TRIPS Agreement and Public Health, 101
- TRIPS Council, 16–29
- American Cyanamid v. Ethicon Ltd.*, 128
- American Declaration of the Rights and Duties of Man, 78–9
- Anti-Counterfeit Act, Kenya, 109–13
- ARIPO. *See* African Regional Intellectual Property Organization
- Association for Molecular Pathology v. Myriad Genetics, Inc.*, 57–8
- Attas, Daniel, 38–64
- Australia, 82
- Australia-Plain Packaging* case, 102
- Austria, patent law in, 11
- Aventis v. Cipla*, 128–31
- azithromycin dihydrate, 109–12

- Barratt, Amanda, 65–6
 Basheer, Shammad, 148–9
Bayer Corporation v. Union of India, 156–9
Bayer v. India, 63
 Berne Convention, 78
 bilateral agreements
 with developing countries, 7–8
 free trade agreements, 93–4
 Bolivia, 28
 Brazil
 Industrial Property Law of 1996, 15–16
 article 68(1)(I), 98
 pharmaceutical patent law in, 98
Bristol-Myers Squibb Co. v. Dr BPS Reddy and others, 157
- cancer, in developing countries, 1–2
 Cassin, Rene, 78
 CESCR. *See* Committee on Economic, Social and Cultural Rights
 Chand, Bakshi Tek, 134–5
 Colombia, 82
 Committee on Economic, Social and Cultural Rights (CESCR), 8–9
 General Comment No. 14, 9, 66, 70, 99, 111, 145–6
 General Comment No. 17, 75–7
 material and moral interests of authors and inventors under, 77–8
 right to health under, 70–1
 compulsory licences
 drug costs influenced by, 63
 in India, 153–6
 under Paris Convention, 12–13
Confederation of Ex-Servicemen Associations and others v. Union of India and others, 142
 constitutions. *See specific countries*
Consumer Education & Research Centre and others v. Union of India and others, 139–40
 copyright law
 derivative works under, 34–5
 patent rights and, 49–50
 serial collaborations under, 34–5
 solitary romantic authorship, 34–6
 as speech restriction, 65
 utilitarianism and, 49–50
 cosmeceutical research, 51
 Cuba, 28, 82
 Czechoslovakia, 87
- Dam, Kenneth, 48–9
 Department of Trade and Industry, in South Africa, 119–21
 derivative works, under copyright law, 34–5
 Desierto, Diane, 102–3
- developing countries. *See also* India; Kenya; least-developed countries; South Africa; *specific countries*
 access to medicines in, 1–4, 28
 government role in, 2
 health spending on, 1
 household costs and, 1
 bilateral agreements with, 7–8
 cancer in, 1–2
 Draft Ministerial Declaration, TRIPS Agreement, 17–18
 HIV/AIDS in, 1–2
 income distribution in, 5
 national patent regimes in, 5
 patent policy space in, 4
 patent rights in, 3–4
 regional agreements with, 7–8
 Doha Declaration, 19–24, 95–6
 model of human rights and, 24
 Paragraph 4, 66
 TRIPS Agreement and Public Health, 101
 Dominican Republic, 28, 86
 Drahos, Peter, 43–4, 47–8, 77
 drug production
 patent law regimes and, 9–10
 pricing strategies and, 42
 drugs. *See also* generic drugs; *specific drugs*
 costs of, compulsory licences as influence on, 63
 under World Health Organization guidelines, 71
 World Trade Organization on, 8
- eBay Inc. v. MercExchange LLC*, 128
 Ecuador, 28, 81–2
 Edison, Thomas, 33
 evergreening, of pharmaceutical patents, 147–8
- “failure to work,” under Paris Convention, 12–13
 FCTC. *See* Framework Convention on Tobacco Control
 Federation of Malaya, 82–7
 Framework Convention on Tobacco Control (FCTC) (WTO), 102
 France, 82–4
 patent law in, 6
 pharmaceutical patent law in, 135–6
 free trade agreements, bilateral, 93–4
- G77. *See* Summit of the Heads of State and Government of the Group of 77
 generic drugs, 41–2, 98
 in India, 152, 156–9
 in Kenya, 110–11
 under Mission for Essential Drugs and Supplies, 105–6

- Germany
 patent law in, 6
 pharmaceutical patent law in, 135–6
- Ghosh, Shubha
 on intellectual property rights, 36
 regulatory theory of, 52–5
 on model of civic participation, 59–61
 on model of expertise, 56–9
 on model of management, 63–4
 on model of market failure, 61–3
 on regulatory theory of patent rights, 52–5
 on socio-centric theory of invention, 36
- Glivec, 148
- Grover, Anand, 110–11, 143–4, 148–9
- Ha-Joon Chang, 4
- Halewood, Michael, 13
- Hegel, Georg Wilhelm Friedrich, on patent rights, 42–8
 acts of will and, abandonment of property through, 43–4
 categorization of intellectual property, 46
 personality theory of property rights, 42–4, 46–7
 on socio-centric theory of invention, 44
 transmission of knowledge as social process, 45
 utilitarian approach, 44
- Helfer, Laurence, 72–4
- heroic theory of invention, 32–3
- Hettinger, Edwin, 39, 49
- HIV/AIDS
 in Kenya, 1–2, 113
 in South Africa, 1–2, 123–4
 UNAIDS estimations, 1–2
- Hoen, Ellen 't, 2
- Hoffmann-La Roche Ltd v. Cipla Ltd*, 128, 159–63
- human rights. *See also* right to health
 intellectual property rights as, 72–88, 92
 in Kenya, intellectual property rights as, 113–16
 model of human rights
 Doha Declaration and, 24
 patent laws and, 9
 regulatory theory of intellectual property and, 64–7
 TRIPS Agreement and, compatibility with, 69
 patent rights and, 72–94
 approaches to, 72–88
 coexistence approach to, 73–4, 92–3
 integrated approach to, 73
 subjugation approach to, 72–4, 94
 primacy of human rights law, 73–4
- Huygens, Christiaan, 33
- ICESCR. *See* International Covenant on Economic, Social and Cultural Rights
- income distribution, in developing countries, 5
- Indacaterol, 160–1
- India, 87
Bayer v. India, 63
 cancer in, 1–2
 colonial history of, 133
 generic drugs in, 152, 156–9
 industrialization policy in, 133–4
 International Covenant on Economic, Social and Cultural Rights and, 143–4
 Mission for Essential Drugs and Supplies, 105–6
 model of human rights in, adjudication of
 patent disputes and, 147–63
Bayer Corporation v. Union of India, 156–9
Bristol-Myers Squibb Co. v. Dr BPS Reddy and others, 157
Hoffmann-La Roche Ltd v. Cipla Ltd, 159–63
Natco v. Bayer, 153–6
Novartis v. Cipla Ltd, 160–1
Novartis v. Union of India, 61, 147–52
 pharmaceutical patent law in, 96–7, 134–8
 balance of convenience framework, 159–63
 colonial history as influence on, 134–5
 compulsory licences in, 153–6
 drug costs and, 153–6
 exclusion of new forms of known drugs, 147–52
 Intellectual Property Appellate Board and, 154–6
 interim injunctions under, 159–63
 patent linkage and, refusal of recognition of, 156–9
 reforms of, 135–6
 right to health in, 138–47
Confederation of Ex-Servicemen Associations and others v. Union of India and others, 142
Consumer Education & Research Centre and others v. Union of India and others, 139–40
 under Indian Constitution, 138–9, 146
Mohd. Ahmed (Minor) v. Union of India and others, 142–4
Paschim Banga Khet Samity v. State of West Bengal, 140
 prohibition of justiciability and, 139
 reasonableness approach to, 142
State of Punjab and others v. Ram Lubhaya Bagga, 140–2, 144
 TRIPS Agreement and, 137–8
 in World Trade Organization, 137
- Indian Patent Act (1911), 134
- Indian Patent Act (1970)
 amendments to, 134, 147–8
 model of expertise and, 59
 section 3(c), 57

- Indian Patent Act (1970) (cont.)
 - section 3(d), 60–1, 68, 95, 97, 147, 149–52
 - section 5, 136
 - section 25(1), 60
 - section 25(2), 60–1
 - section 32, 53
 - section 47(3), 58
 - section 83, 136–7
 - section 84(1)(c), 97
 - section 107A(a), 157–8
- Industrial Property Act, Kenya (1989), 105
- Industrial Property Act, Kenya (2001)
 - amendments to, 105
 - parallel import mechanisms and, 105–6
 - section 21(3), 57
 - section 23(4), 53
 - section 58(1), 58
 - section 58(2), 64, 107–8
 - section 59, 106–7
 - section 83(d), 59
 - section 83(g), 59
 - section 84(1)(a), 59
 - section 84(1)(b), 59
- Industrial Property Bill of 2020, Kenya, 105
- Industrial Property Law of 1996, Brazil, 15–16
 - article 68(1)(I), 98
- industrialized/developed nations
 - bilateral agreements, with developing countries, 7–8
 - patent law in, 6
 - regional agreements, with developing countries, 7–8
- injunctions
 - in *eBay Inc. v. MercExchange LLC*, 128
 - in *Hoffman-La Roche Ltd v. Cipla*, 128
 - in infringement suits, 159
 - in pharmaceutical patent law, in India, 159–63
- integrated approach, to patent rights, 73
- Intellectual Property Appellate Board (IPAB), in India, 154–6
- intellectual property law
 - incentives approach to, 46–51
 - socio-centric theory of invention and, 36–7
 - as speech restriction, 65
 - in United Kingdom, 67
 - utilitarianism and, 46–51
- intellectual property rights. *See also* patent law; patent rights; patents
 - Ghosh on, 36
 - as human rights, 72–88, 92
 - under international human rights law, 92
 - in Kenya, human rights as, 113–16
 - Locke on, 39
 - patent rights and
 - categorization of intellectual property rights, 46
 - utilitarian justification of, 49
- International Covenant on Economic, Social and Cultural Rights (ICESCR), 6–9
 - Article 2, 28
 - Article 6(1), 81
 - Article 7(a), 77
 - Article 12, 28–30, 66, 72, 111
 - Article 12(1), 70, 101
 - Article 15(1), 74, 83
 - Article 15(1)(c), 75–6, 78, 82–3, 87–9
 - India and, 143–4
 - material and moral interests of authors and inventors under, 75–6, 78, 82–3, 87–9
 - right to health under, 70–1
- international human rights law
 - intellectual property rights under, 92
 - patent rights under, 91–4
- international law, right to health under, 70–2
 - Committee on Economic, Social and Cultural Rights, 70–1
- International Covenant on Economic, Social and Cultural Rights, 70–1
 - obligations under, 71–2
- inventors, material and moral interests of authors and inventors, 76–89
 - under International Covenant on Economic, Social and Cultural Rights, Article 15(1)(c), 75–6, 78, 82–3, 87–9
 - under Universal Declaration of Human Rights, 77–8, 85–9
- IPAB. *See* Intellectual Property Appellate Board
- Italy, 86
- Joint United Nations Programme on HIV/AIDS (UNAIDS), 1–2
- Jordan. *See* US-Jordan Free Trade Agreement
- Kenya. *See also* Industrial Property Act (2001)
 - African Regional Intellectual Property Organization in, 106–7
 - Anti-Counterfeit Act, 109–13
 - cancer in, 1–2
 - Constitution
 - Article 11(2)(c), 113–15
 - Article 22(1), 115
 - Article 23(3)(b), 114
 - Article 40(5), 104, 113–16
 - Article 43(1), 104, 111
 - Article 43(1)(a), 108
 - right to health in, 104
 - generic drugs in, 110–11
 - HIV/AIDS in, 1–2, 113
 - human rights in, intellectual property rights as, 113–16
 - Industrial Property Act (1989), 105

- Industrial Property Bill of 2020, 105
 intellectual property rights in, as human rights, 113–16
 Mission for Essential Drugs and Supplies in, 105–6
 model of human rights in, 117
 in *Patricia Osero Ochieng et al. v. Attorney General*, 109–13
 in *Pfizer v. Cosmos Limited*, 109–12
 pharmaceutical patent law and, 106–13
 right to health in, 104, 111
 parallel import mechanisms in, 105–6
 Patents Registration Act (1933), 104–5
 pharmaceutical patent law in, 104–13
 flexibilities of, 105–6
 model of human rights and, 106–13
 right to health in
 in Kenyan Constitution, 104
 in model of human rights, 104, 111
Royal Media Services Ltd. and Others v. Attorney General and Others, 115–16
Sanitam Services Ltd. v. Tamia Ltd., 114
 Kenya Association of Manufacturers, 110
 Klug, Heinz, 15, 98
 knowledge. *See* transmission of knowledge
- least-developed countries (LDCs), TRIPS Agreement and, 16
 licences. *See* compulsory licences
 Locke, John, 37–8
 on intellectual property rights, 39
 on patent rights, 37–42
 labour and, 36–40
 no loss to others proviso, 40–1
 property theory and, 37–8
 spoilage and waste proviso, 38–42
 value of invention, 39–40
 on self-ownership, 38
- Mandela, Nelson, 15, 98
 material and moral interests of authors and inventors, 76–89
 under International Covenant on Economic, Social and Cultural Rights, Article 15(1)(c), 75–6, 78, 82–3, 87–9
 under Universal Declaration of Human Rights, 77–8, 85–9
 Medicines and Related Substances Control Act, South Africa (1997), 15–16, 98, 126
 section 15(c), 64
 MEDS. *See* Mission for Essential Drugs and Supplies
 Merges, Robert, 49
 Mexico, 12
- Minister of Health v. New Clicks*, 126
 Mission for Essential Drugs and Supplies (MEDS), from India, 105–6
 model of civic participation, 59–61
 model of expertise, 56–9
 Indian Patents Act (1970) and, 59
 patent law and, 57
 model of human rights
 access to medicines and, 165–6
 Doha Declaration and, 24
 in India, in adjudication of patent disputes, 147–63
 Bayer Corporation v. Union of India, 156–9
 Bristol-Myers Squibb Co. v. Dr BPS Reddy and others, 157
 Hoffmann-La Roche Ltd v. Cipla Ltd, 159–63
 Natco v. Bayer, 153–6
 Novartis v. Cipla Ltd, 160–1
 Novartis v. Union of India, 61, 147–52
 in Kenya, 117
 in *Patricia Osero Ochieng et al. v. Attorney General*, 109–13
 in *Pfizer v. Cosmos Limited*, 109–12
 pharmaceutical patent law and, 106–13
 right to health in, 104, 111
 patent laws and, incorporation into, 9, 28–30
 patent policy space and, 165–6
 patent rights in, 91–4
 regulatory theory of intellectual property and, 64–7
 socio-centric perspective of, 164–5
 in South Africa, adjudication of patent disputes and, 127–32
 Aventis v. Cipla, 128–31
 Pfizer v. Cipla Medpro, 127–8
 TRIPS Agreement and, compatibility with, 69
 right to health and, 94–102
 model of management, 63–4
 model of market failure, 61–3
 public goods and, 61–2
 social cost of exclusion in, 62
Mohd. Ahmed (Minor) v. Union of India and others, 142–4
 Morse, Samuel, 33
 Multilateral Agreement on Investment, 4–5
- Natco v. Bayer*, 153–6
 Newcomen, Thomas, 33
 Nexavar, 153–4
 no loss to others proviso, for patent rights, 40–1
Novartis v. Cipla Ltd, 160–1
Novartis v. Union of India, 61, 147–52
 Nunn, Amy, 63

- Ogburn, William, 33–4
 Oguamanam, Chidi, 51
 Ortiz, Campo, 80
- Page, Sheila, 7
 Palmer, Tom, 42
 Papin, Denis, 33
 parallel import mechanisms, 105–6
 Paris Convention for the Protection of Industrial Property of 1883 (Paris Convention)
 Article 2(1), 11–12
 Article 4, 12
 Article 5A(2), 12–13
 compulsory licences under, 12–13
 “failure to work” under, 12–13
 harmonization framework for, 14
 mutual independence of patents under, 12
 patent policy space and, 6–7
 revisions of, 11
 World Intellectual Property Organization and, 11
Paschim Banga Khet Samity v. State of West Bengal, 140
 patent law. *See also* socio-centric theory of invention
 in Austria, 11
 in developed nations, 6
 in developing countries, 5
 drug production and, 9–10
 globalization of, 10–14
 model of expertise and, 57
 model of human rights and, incorporation of, 9, 28–30
 socio-centric theory of invention and, 67–8
 theoretical approaches to, 32–7
 heroic theory of invention, 32–3
 precursor inventions in, 33
 solitary romantic authorship, 34–6
 patent linkage, 95
 in India, refusal of recognition of, 156–9
 patent policy space, 4–24
 access to medicines and, 4–10
 in developing countries, 4
 historical background for, 10–24
 historical perspective on, 4–5
 model of human rights and, 165–6
 Multilateral Agreement on Investment and, 4–5
 Paris Convention and, 6–7, 11–14
 preservation of, 165–6
 reclamation of, at multilateral level, 14–24
 shrinkage of, 5–6, 8
 technological transfer and, 10
 TRIPS Agreement and, 5–7, 14–24
 development of patent policy before, 10–14
 UN Conference on Trade and Development
 definition of, 4
 World Trade Organization framework for, 5–6
 patent rights. *See also* regulatory theory of patent rights
 access to medicine and, 41–2
 in developing countries, 3–4
 Hegel on, 42–8
 acts of will, abandonment of property
 through, 43–4
 categorization of intellectual property, 46
 personality theory of property rights, 42–4, 46–7
 on socio-centric theory of invention, 44
 transmission of knowledge as social process, 45
 utilitarian approach, 44
 as human rights, 72–94
 approaches to, 72–88
 coexistence approach to, 73–4, 92–3
 integrated approach to, 73
 subjugation approach to, 72–4, 94
 intellectual property rights and
 categorization of, Hegel on, 46
 utilitarian justification of, 49
 under international human rights law, 91–4
 Locke on, 37–42
 on labour, 36–40
 no loss to others proviso, 40–1
 property theory and, 37–8
 spoilage and waste proviso, 38–42
 value of invention, 39–40
 material and moral interests of authors and
 inventors, 76–89
 under International Covenant on Economic, Social and Cultural Rights, Article 15(1)(c), 75–6, 78, 82–3, 87–9
 under Universal Declaration of Human Rights, 77–8, 85–9
 in model of human rights, 91–4
 socio-centric theory of invention and
 Hegel on, 44
 utilitarianism and, 50
 under TRIPS Agreement, 2–3
 under Universal Declaration of Human Rights, 76–89
 material and moral interests of authors and
 inventors, 77–8
 utilitarianism and, 48–51
 copyright law and, 49–50
 Hegel on, 44
 intellectual property as incentives approach, 46–51
 for intellectual property rights, 49–51

- public goods and, 48
- socio-centric theory of invention and, 50
- patents. *See also* patent law; patent policy space; pharmaceutical patents; *specific topics*
- mutual independence of, 12
- Patents Act, South Africa, 130–1
 - amendments to, 118
 - section 25(2), 57, 119
 - TRIPS Agreement and, 118–19
- Patents Registration Act (1933), Kenya, 104–5
- Patricia Osero Ochieng et al. v. Attorney General*, 109–13
- Pegasys, 61
- personality theory of property rights, 42–4, 46–7
- Pfizer v. Cipla Medpro*, 127–8
- Pfizer v. Cosmos Limited*, 109–12
- pharmaceutical patents, legal regimes for
 - in Brazil, 98
 - evergreening of patents, 147–8
 - in Kenya, 104–13
 - flexibilities of, 105–6
 - model of human rights and, 106–13
 - in South Africa, 118–21, 131–2
 - Department of Trade and Industry and, 119–21
 - filtering mechanisms in, 120
 - Soobramoney v. Minister of Health*, 121, 123
 - Treatment Action Campaign* case, 123, 125–6
 - in U.S., 98
 - United States Trade Representative, 96–7
- policy space. *See* patent policy space
- poor health, poverty and, 1
- poverty
 - access to medicine and, 1
 - poor health and, 1
- precursor inventions, 33
- primacy of human rights law, 73–4
- property rights. *See also* intellectual property rights
 - personality theory of, 42–4, 46–7
- property theory, patent rights and, 37–8
- public goods
 - model of market failure and, 61–2
 - patent rights and, 48
- Radin, Margaret, 42, 45–6
- Re Certification of the Constitution of the Republic of South Africa*, 1996, 92, 127
- regional agreements, with developing countries, 7–8
- regulatory theory of intellectual property
 - exclusive rights of creators, 56
 - Ghosh on, 52–5
 - model of civic participation and, 59–61
 - model of expertise, 56–9
 - Indian Patents Act (1970) and, 59
 - patent law and, 57
 - model of expertise and, 56–9
 - model of human rights, 64–7
 - model of management, 63–4
 - model of market failure, 61–3
 - public goods and, 61–2
 - social cost of exclusion in, 62
 - socio-centric theory of invention and, 55
 - regulatory theory of patent rights, 48–67
 - applications process, for patents, 53
 - Ghosh on, 52–5
 - patent infringement claims, 53–5
 - right of publicity law, as speech restriction, 65
 - right to health, 25–7. *See also* India
 - under international law, 70–2
 - Committee on Economic, Social and Cultural Rights, 70–1
 - International Covenant on Economic, Social and Cultural Rights, 70–1
 - obligations under, 71–2
 - in Kenya, 104, 111
 - in South Africa, 121–6
 - Minister of Health v. New Clicks*, 126
 - reasonableness approach to, 123–5
 - TRIPS Agreement and, 94–102
 - model of human rights, 94–102
 - World Trade Organization dispute settlement panels and, 100–2
- right to science and culture, 89–91
 - access in, 90
- rights. *See* human rights; patent rights; *specific rights*
- Roussel-Uclaf v. G. D. Searle & Co.*, 108–9, 128
- Royal Media Services Ltd. and Others v. Attorney General and Others*, 115–16
- Sanitam Services Ltd. v. Tamia Ltd.*, 114
- Savery, Thomas, 33
- Second Treatise of Government* (Locke), 37–8
- self-ownership, 38. *See also* property rights
- serial collaborations, under copyright law, 34–5
- social cost of exclusion, model of market failure and, 62
- socio-centric theory of invention, 33–4, 36, 39–40
 - Ghosh on, 36
 - intellectual property law and, 36–7
 - patent law policy and, 67–8
 - patent rights and, 44
 - utilitarianism and, 50
 - technological advances in, 36
 - users in, 36
- solitary romantic authorship, 34–6
- Soobramoney v. Minister of Health*, 121, 123

- Sorafenib, 153
- South Africa
- cancer in, 1–2
 - Constitution of 1996
 - Section 27(1)(a), 121–5
 - Section 27(2), 121–5
 - Section 27(3), 121–2
 - HIV/AIDS in, 1–2, 123–4
 - Medicines and Related Substances Control Act, 15–16, 98, 126
 - section 15(c), 64
 - model of human rights in, adjudication of
 - patent disputes and, 127–32
 - Aventis v. Cipla*, 128–31
 - Pfizer v. Cipla Medpro*, 127–8
 - Patents Act, 130–1
 - amendments to, 118
 - section 25(2), 57, 119
 - TRIPS Agreement and, 118–19
 - pharmaceutical patent law in, 118–21, 131–2
 - Department of Trade and Industry and, 119–21
 - filtering mechanisms in, 120
 - Soobramoney v. Minister of Health*, 121, 123
 - Treatment Action Campaign* case, 123, 125–6
 - Re Certification of the Constitution of the Republic of South Africa*, 1996, 92, 127
 - right to health in, 121–6
 - Minister of Health v. New Clicks*, 126
 - reasonableness approach to, 123–5
 - Treatment Action Campaign (NGO), 130
 - pharmaceutical patent law cases, 123, 125–6
 - spoilage and waste proviso, for patent rights, 38–42
 - Sri Lanka, 28
 - State of Punjab and others v. Ram Lubhaya Bagga*, 140–2, 144
 - subjugation approach, to patent rights, 72–4, 94
 - Summit of the Heads of State and Government of the Group of 77 (G77), 5
 - Sunder, Madhavi, 50–1
 - Switzerland
 - patent law in, 6
 - pharmaceutical patent law in, 98
 - TAC. *See* Treatment Action Campaign
 - technology transfer, patent policy space and, 10
 - Thomas, Dorothy, 33–4
 - trade secret law, as speech restriction, 65
 - trademark law, as speech restriction, 65
 - transmission of knowledge, as social process, 45
 - Treatment Action Campaign (TAC) (NGO), 130
 - pharmaceutical patent law cases, 123, 125–6
 - Treatment Action Campaign* case, 123, 125–6
 - TRIPS Agreement. *See* Agreement on Trade-Related Aspects of Intellectual Property Rights
 - TRIPS Agreement and Public Health, 101
 - TRIPS Council, 16
 - Tushnet, Rebecca, 49–50
 - UDHR. *See* Universal Declaration of Human Rights
 - Uganda, 28
 - U.K. *See* United Kingdom
 - UN. *See* United Nations
 - UNAIDS. *See* United Nations
 - UNCTAD. *See* United Nations
 - UNDESA. *See* United Nations
 - UNESCO. *See* United Nations
 - Union of Soviet Socialist Republics (USSR), 86
 - United Kingdom (U.K.)
 - intellectual property law, 67
 - pharmaceutical patent law in, 98
 - United Nations (UN)
 - Committee on Economic, Social and Cultural Rights, 8–9
 - Conference on Trade and Development, 4
 - Department of Economic Social Affairs, 7
 - Education, Scientific and Cultural Organization, 82–6
 - Joint United Nations Programme on HIV/AIDS, 1–2
 - United States (U.S.)
 - Association for Molecular Pathology v. Myriad Genetics, Inc.*, 57–8
 - bilateral free trade agreements, 93–4
 - pharmaceutical patent law in, 98
 - United States Trade Representative, 96–7
 - US-Jordan Free Trade Agreement, 93
 - United States Trade Representative (USTR), 96–7
 - Universal Copyright Convention of 1952, 87
 - Universal Declaration of Human Rights (UDHR)
 - Article 17, 77
 - Article 23(1), 81
 - Article 27(2), 74–99
 - patent rights under, 76–89
 - material and moral interests of authors and inventors, 77–8
 - Uruguay Round, WTO, 7
 - U.S. *See* United States
 - users, in socio-centric theory of invention, 36
 - US-Jordan Free Trade Agreement, 93
 - USSR. *See* Union of Soviet Socialist Republics
 - USTR. *See* United States Trade Representative
 - utilitarianism, patent rights and, 48–51
 - copyright law and, 49–50
 - Hegel on, 44

| | |
|---|--|
| intellectual property as incentives approach, 46–51 | World Trade Organization (WTO), 2 |
| for intellectual property rights, 49–51 | dispute settlement panels, 100–2 |
| public goods and, 48 | on essential drugs, 8 |
| socio-centric theory of invention and, 50 | Framework Convention on Tobacco Control, 102 |
| Venezuela, 28 | India in, 137 |
| Watt, James, 33–4 | patent policy space framework, 5–6 |
| WHO. <i>See</i> World Health Organization | Uruguay Round, 5–6 |
| WIPO. <i>See</i> World Intellectual Property Organization | Wright, Orville, 33 |
| World Health Organization (WHO), 71 | Wright, Wilbur, 33 |
| World Intellectual Property Organization (WIPO), 11 | WTO. <i>See</i> World Trade Organization |
| | Yu, Peter, 89 |
| | Yugoslavia, 84 |